Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
South Korea
The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul, Eunpyeong-gu Bundang CHA General Hospital, Seongnam-si, Gyeonggi-do Last updated November 2024